Corcept Therapeutics (NASDAQ:CORT – Get Rating) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, May 5th. Analysts expect the company to announce earnings of $0.23 per share for the quarter. Corcept Therapeutics has set its FY 2022 guidance at EPS.
Corcept Therapeutics (NASDAQ:CORT – Get Rating) last announced its quarterly earnings data on Tuesday, February 15th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.04. The firm had revenue of $98.82 million for the quarter, compared to analysts’ expectations of $101.17 million. Corcept Therapeutics had a net margin of 30.74% and a return on equity of 23.08%. During the same period last year, the firm earned $0.20 earnings per share. On average, analysts expect Corcept Therapeutics to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Shares of NASDAQ CORT opened at $21.25 on Friday. The company’s fifty day moving average is $23.71 and its 200-day moving average is $21.23. The stock has a market cap of $2.45 billion, a price-to-earnings ratio of 23.88, a P/E/G ratio of 2.32 and a beta of 0.54. Corcept Therapeutics has a twelve month low of $15.82 and a twelve month high of $25.68.
A number of hedge funds and other institutional investors have recently modified their holdings of CORT. Stifel Financial Corp lifted its stake in shares of Corcept Therapeutics by 37.9% in the fourth quarter. Stifel Financial Corp now owns 21,156 shares of the biotechnology company’s stock valued at $419,000 after buying an additional 5,810 shares in the last quarter. California State Teachers Retirement System raised its holdings in shares of Corcept Therapeutics by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 145,537 shares of the biotechnology company’s stock valued at $2,882,000 after purchasing an additional 2,652 shares during the last quarter. D. E. Shaw & Co. Inc. increased its holdings in Corcept Therapeutics by 74.5% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 393,748 shares of the biotechnology company’s stock worth $7,796,000 after buying an additional 168,071 shares during the last quarter. Morgan Stanley increased its holdings in Corcept Therapeutics by 21.1% during the second quarter. Morgan Stanley now owns 604,124 shares of the biotechnology company’s stock worth $13,291,000 after buying an additional 105,152 shares during the last quarter. Finally, Norges Bank purchased a new stake in Corcept Therapeutics during the fourth quarter worth about $16,307,000. 69.10% of the stock is currently owned by institutional investors and hedge funds.
A number of brokerages have recently weighed in on CORT. Truist Financial began coverage on shares of Corcept Therapeutics in a research report on Friday, January 28th. They set a “buy” rating and a $30.00 price target on the stock. Canaccord Genuity Group began coverage on shares of Corcept Therapeutics in a research report on Wednesday, February 2nd. They set a “buy” rating and a $30.00 price target on the stock. StockNews.com assumed coverage on shares of Corcept Therapeutics in a research report on Thursday, March 31st. They set a “strong-buy” rating on the stock. Finally, HC Wainwright restated a “buy” rating and set a $29.00 price objective on shares of Corcept Therapeutics in a report on Wednesday, February 16th. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $27.25.
About Corcept Therapeutics (Get Rating)
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.
- Get a free copy of the StockNews.com research report on Corcept Therapeutics (CORT)
- Rogers Communication Stock Should Be Launching Higher
- Iridium Communications Stock is Ready to Return to Orbit
- O’Reilly Automotive Hits A Pothole
- There’s An Institutional Floor In Keurig Dr. Pepper
- Ford Falls Despite Optimistic Outlook
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.